当前位置: X-MOL 学术Ann. Rheum. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis
Annals of the Rheumatic Diseases ( IF 27.4 ) Pub Date : 2019-01-30 , DOI: 10.1136/annrheumdis-2019-215009
Zachary Scott Wallace 1, 2, 3 , Hyon Choi 2, 3, 4 , John H Stone 3, 4
Affiliation  

We read with interest the article ‘Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis’ by Kronbichler et al .1 Severe infections continue to be a significant cause of morbidity and mortality in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), and we commend the authors for pursuing this study. However, we have several concerns regarding their methodologies. First, more than 90% of patients with AAV analysed were prevalent cases. This may limit the generalisability of their findings to incident cases in whom there has been no prior treatment with cyclophosphamide or other immunosuppressive agents. As the authors note, there was an average delay of 4 years …

中文翻译:

利妥昔单抗后严重感染的风险和抗菌药物预防的效果

我们饶有兴趣地阅读了 Kronbichler 等人撰写的文章“甲氧苄啶-磺胺甲恶唑预防可预防利妥昔单抗治疗抗中性粒细胞胞浆抗体相关血管炎后的严重/危及生命的感染”。1 严重感染仍然是抗肿瘤患者发病率和死亡率的重要原因-中性粒细胞胞质抗体相关血管炎 (AAV),我们赞扬作者进行这项研究。但是,我们对他们的方法有几个担忧。首先,超过 90% 的 AAV 分析患者是流行病例。这可能会限制他们的发现对先前没有用环磷酰胺或其他免疫抑制剂治疗的事件病例的普遍性。正如作者所指出的,平均延迟了 4 年……
更新日期:2019-01-30
down
wechat
bug